Overview

Testosterone Replacement Therapy (TRT) is a hormone therapy, not a peptide -- included here as a reference guide because it is central to the hormones and endocrine topic and frequently discussed alongside performance and metabolic compounds.

Indication and diagnosis. The Endocrine Society recommends diagnosing hypogonadism only in men with both symptoms/signs of testosterone deficiency and unequivocally, consistently low morning serum testosterone on at least two separate measurements (Bhasin et al., 2018). Causes are classified as primary (testicular) or secondary (hypothalamic-pituitary). TRT is not recommended for men with normal testosterone or for non-specific age-related symptoms without biochemical confirmation.

Formulations. Common options include intramuscular or subcutaneous testosterone cypionate/enanthate esters (typically dosed weekly or split), transdermal 1-2% gels applied daily, transdermal patches, buccal and nasal preparations, long-acting intramuscular testosterone undecanoate given every 10-14 weeks, and subcutaneous testosterone pellets implanted every 3-6 months. Choice depends on patient preference, pharmacokinetic stability and cost.

Benefits. In genuinely hypogonadal men, TRT improves libido and sexual function, increases lean mass and reduces fat mass, improves bone mineral density, and can improve mood and energy. Effects on hard cardiovascular endpoints remain an area of ongoing study.

Risks and monitoring. Testosterone therapy raises hematocrit (risk of erythrocytosis), can suppress spermatogenesis and fertility, may worsen untreated obstructive sleep apnea, and requires prostate surveillance. Guidelines advise checking testosterone, hematocrit and PSA at baseline, then at 3-6 months and periodically thereafter, with dose adjustment to keep levels in the mid-normal range. TRT is generally avoided in men seeking fertility, and in those with untreated prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or a recent cardiovascular event.

Note on dosing: structured dosing for this entry was set in a prior enrichment pass and is intentionally not overwritten here; clinicians titrate to symptom response and mid-normal serum testosterone.

Mechanism of Action

By returning serum testosterone to the mid-normal range, TRT re-engages androgen-receptor-mediated transcription in muscle, bone, CNS, and reproductive tissue. Peripheral conversion by aromatase to estradiol and by 5-alpha-reductase to dihydrotestosterone contributes to bone maintenance and to androgenic effects respectively. Negative feedback on GnRH/LH/FSH is the reason exogenous testosterone reduces intratesticular testosterone and impairs fertility, which is why men wanting to preserve fertility may instead be managed with agents that stimulate the axis.

Reconstitution Calculator

Safety Profile

Safety Profile: TRT (Testosterone Replacement Therapy)

Common Side Effects

• Acne and oily skin (androgen-stimulated sebaceous glands)
• Fluid retention and weight gain
• Erythrocytosis/polycythemia (increased red blood cell count—the most common clinically significant side effect)
• Injection site pain, nodules, and irritation (injectable forms); skin irritation (topical gels/patches)
• Mood changes: irritability, aggression, or emotional lability
• Gynecomastia (estrogen conversion via aromatase)
• Testicular atrophy and reduced sperm count (suppression of endogenous gonadotropins)
• Increased body hair growth

Serious Adverse Effects

• Polycythemia: Hematocrit >54% increases stroke, DVT, and pulmonary embolism risk; most dangerous side effect requiring regular monitoring
• Cardiovascular risk: FDA-required label warning for increased risk of heart attack and stroke; TRAVERSE trial (2023) showed no excess MACE in men with CV risk factors, though ongoing monitoring advised
• Hepatotoxicity: Primarily with oral 17-alpha-alkylated androgens (methyltestosterone); injectable and transdermal forms carry minimal hepatic risk
• Sleep apnea: Worsening or new-onset obstructive sleep apnea
• Prostate effects: May accelerate growth of existing prostate cancer (does not cause de novo prostate cancer based on current evidence)
• Infertility: Suppresses spermatogenesis; may be irreversible in some men after prolonged use
• Venous thromboembolism

Contraindications

• Prostate cancer (active or suspected) or breast cancer in men
• Hematocrit > 50% at baseline
• Severe untreated obstructive sleep apnea
• Uncontrolled heart failure (NYHA class III–IV)
• Desire for fertility within 6–12 months (use hCG or clomiphene alternatives)
• Pregnancy (Category X; virilization of female fetus)
• Women (except specific off-label indications under specialist care)

Drug Interactions

• Anticoagulants (warfarin): Testosterone potentiates anticoagulation; INR monitoring required
• Insulin and oral hypoglycemics: Testosterone improves insulin sensitivity; dose reduction may be needed
• Corticosteroids: Additive fluid retention and edema
• 5-alpha reductase inhibitors (finasteride, dutasteride): May partially counteract androgenic effects (sometimes intentionally combined for hair loss)
• Aromatase inhibitors (anastrozole): Commonly co-prescribed to manage estradiol; not FDA-approved for this indication

Population-Specific Considerations

• Monitoring schedule: CBC/hematocrit, PSA, testosterone, estradiol, and lipids at 3, 6, and 12 months, then annually
• Hypogonadal men: Only prescribe for confirmed hypogonadism (two morning testosterone levels <300 ng/dL with symptoms)
• Cardiovascular patients: Individualized risk-benefit assessment; TRAVERSE trial provides some reassurance
• Fertility preservation: Use hCG or SERMs (clomiphene/enclomiphene) as alternatives when fertility desired
• Elderly (>65): Higher polycythemia risk; consider lower doses and more frequent monitoring
• Route selection: IM injections (most cost-effective), topical gels (steady levels), subcutaneous pellets (convenience), nasal (natesto—avoids first pass)
• Abuse potential: Schedule III controlled substance; supraphysiological doses carry substantially higher risks

Pharmacokinetic Profile